Race intensifies to lead next wave of obesity drugs as trial results loom

Race intensifies to lead next wave of obesity drugs as trial results loom is a pharma and life sciences industry update from PharmaVoice. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Kelly Bilodeau · 2026-05-18

As next-generation GLP-1 contenders rise, key readouts are on the way from Pfizer, Viking Therapeutics and Eli Lilly.

Source: PharmaVoice